VTYX - NASDAQ
Ventyx Biosciences, Inc.
$14.00
+0.0000%Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
At a Glance
Live SnapshotVentyx Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Ventyx Biosciences, Inc. Balance Sheet
VTYX • NASDAQ
| Ventyx Biosciences, Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
CURRENT ASSETS | ||||||
27.3M | 51.6M | 64.8M | 70.8M | 244K | 309K | |
190.1M | 200.6M | 253.1M | 187.8M | 0.0 | 0.0 | |
217.3M | 252.2M | 317.9M | 258.6M | 244K | 309K | |
1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 4.4M | 1K | 40K | |
11.3M | 12.1M | 12.7M | 0.0 | 0.0 | 0.0 | |
229.6M | 264.3M | 330.7M | 263M | 245K | 349K | |
NON-CURRENT ASSETS | ||||||
10.3M | 12.3M | 1.9M | 254K | 0.0 | 0.0 | |
35.6M | 0.0 | 38.7M | 28.1M | 0.0 | 0.0 | |
1M | 1.1M | 96K | 60K | 0.0 | 0.0 | |
46.9M | 13.3M | 40.7M | 28.5M | 0.0 | 0.0 | |
276.6M | 277.7M | 371.4M | 291.5M | 245K | 349K | |
LIABILITIES | ||||||
CURRENT LIABILITIES | ||||||
3.1M | 5.8M | 6.4M | 4.7M | 1.1M | 362K | |
3.1M | 5.8M | 6.4M | 4.7M | 1.1M | 362K | |
8.6M | 15.5M | 9.5M | 7.6M | 301K | 269K | |
1.1M | 1M | 412K | 0.0 | 0.0 | 0.0 | |
12.8M | 22.3M | 16.4M | 12.3M | 1.4M | 631K | |
NON-CURRENT LIABILITIES | ||||||
0.0 | 0.0 | 0.0 | 0.0 | 12.6M | 3.8M | |
0.0 | 0.0 | 0.0 | 0.0 | 16.8M | 0.0 | |
9.7M | 11.5M | 1.1M | 0.0 | 29.5M | 3.8M | |
10.8M | 12.5M | 1.6M | 0.0 | 0.0 | 0.0 | |
22.5M | 33.8M | 17.5M | 12.3M | 30.9M | 4.5M | |
SHAREHOLDERS' EQUITY | ||||||
7K | 6K | 6K | 5K | 0.0 | 0.0 | |
808.2M | 663.2M | 581.2M | 397.1M | 1.8M | 199K | |
-554.3M | -419.2M | -226.2M | -117.8M | -32.5M | -4.3M | |
157K | -50K | -1.1M | -58K | 0.0 | 0.0 | |
254M | 243.9M | 353.9M | 279.2M | -30.7M | -4.1M | |
254M | 243.9M | 353.9M | 279.2M | -30.7M | -4.1M | |
SUMMARY | ||||||
276.6M | 277.7M | 371.4M | 291.5M | 245K | 349K | |
225.7M | 200.6M | 291.8M | 215.9M | 0.0 | 0.0 | |
10.8M | 12.5M | 1.6M | 0.0 | 12.6M | 3.8M | |
-16.5M | -39.1M | -63.3M | -70.8M | 12.4M | 3.5M | |
71,358,635 | 71,358,635 | 71,358,635 | 71,358,635 | 71,358,635 | 71,358,635 |
SEC Filings
VTYX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 22, 2025 | October 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your VTYX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.